Allos Therapeutics Announces Interim Data From Phase 1 Study Of PDX In Patients With Relapsed Or Refractory Cutaneous T-Cell Lymphoma Allos Therapeutics, Inc. (NASDAQ: ALTH) announced the presentation of interim data from its Phase 1 study of PDX (pralatrexate) with vitamin B12 and folic acid supplementation in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL), at the 10th International Conference on Malignant Lymphoma in Lugano, Switzerland, June 4-7, 2008.
Source: www.medicalnewstoday.comLabels: No Prescription, Online Pharmacy
# posted by Network @ 6:00 PM
